ノート
乳がん術前・術後補助化学療法に対する相対用量強度の影響に関する研究
2019 年 45 巻 8 号 p. 485-490
詳細
2019 年 45 巻 8 号 p. 485-490
Maintaining Average Relative Dose Intensity (ARDI) in neo adjuvant chemotherapy and adjuvant chemotherapy in breast cancer leads to an improved therapeutic effect, but few patients have clear indicators.
In the study we report the effect of ARDI on the treatment effect in EC followed by weekly nab-PTX therapy. Our subjects were 48 patients with breast cancer who received EC followed by weekly nab-PTX therapy in neo adjuvant chemotherapy and adjuvant chemotherapy at Nihon University Itabashi Hospital between 2012 and 2017.
In the study we compared Disease-free survival (DFS) and adverse effect rates between the two groups of the ARDI ≥ 90％ group and ARDI < 90％ group.
The patients in the ARDI ≥ 90％ group exhibited significant difference in 2 years DFS and 3 years DFS (2 years DFS: P = 0.0095, 3 years DFS: P = 0.0019) as compared to the ARDI < 90％ group. In terms of the adverse effect incidence rate, pathological subtype by type DFS, there was no difference between the two groups. Maintaining ARDI at 90％ or higher in this study leads to improvement of the therapeutic effect.
